Rankings
▼
Calendar
RNAC Q4 2021 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
RNAC
Cartesian Therapeutics, Inc.
$218M
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$30M
+150.5% YoY
Gross Profit
$30M
100.0% margin
Operating Income
$4M
13.6% margin
Net Income
$12M
40.9% margin
EPS (Diluted)
$2.96
QoQ Revenue Growth
+22.6%
Cash Flow
Operating Cash Flow
-$31M
Free Cash Flow
-$32M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$160M
Total Liabilities
$137M
Stockholders' Equity
$23M
Cash & Equivalents
$114M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$30M
$12M
+150.5%
Gross Profit
$30M
$12M
+150.5%
Operating Income
$4M
-$8M
+151.6%
Net Income
$12M
-$15M
+179.2%
← FY 2021
All Quarters
Q1 2022 →